{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:43:57Z","timestamp":1788860637774,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Liposomal amphotericin B (L-AMB), a broad-spectrum antifungicidal drug, is often used to treat fungal infections. However, clinical evidence of its use in patients with renal dysfunction, especially those receiving renal replacement therapy (RRT), is limited. Therefore, we evaluated the usage and occurrence of adverse reactions during L-AMB therapy in patients undergoing RRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using claims data and laboratory data, we retrospectively evaluated patients who were administered L-AMB. The presence of comorbidities, mortality rate, treatment with L-AMB and other anti-infective agents, and the incidence of adverse reactions were compared between patients receiving RRT, including continuous renal replacement therapy (CRRT) and maintenance hemodialysis (HD), and those that did not receive RRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 900 cases met the eligibility criteria: 24, 19, and 842 cases in the maintenance HD, CRRT, and non-RRT groups, respectively. Of the patients administered L-AMB, mortality at discharge was higher for those undergoing either CRRT (15\/19; 79%) or maintenance HD (16\/24; 67%) than for those not receiving RRT (353\/842; 42%). After propensity score matching, the average daily and cumulative dose, treatment duration, and dosing interval for L-AMB were not significantly different between patients receiving and not receiving RRT. L-AMB was used as the first-line antifungal agent for patients undergoing CRRT in most cases (12\/19; 63%). Although the number of subjects was limited, the incidence of adverse events did not markedly differ among the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>L-AMB may be used for patients undergoing maintenance HD or CRRT without any dosing, duration, or interval adjustments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-020-01989-3","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T17:02:50Z","timestamp":1605114170000},"page":"279-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study"],"prefix":"10.1007","volume":"25","author":[{"given":"Yoko","family":"Obata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaro","family":"Wakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1080\/13693780400025237","volume":"43","author":"M Kleinberg","year":"2005","unstructured":"Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol. 2005;43:S289\u201394.","journal-title":"Med Mycol"},{"key":"1989_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.qco.0000136935.13662.af","volume":"17","author":"JM Brown","year":"2004","unstructured":"Brown JM. Fungal infections in bone marrow transplant patients. Curr Opin Infect Dis. 2004;17:347\u201352.","journal-title":"Curr Opin Infect Dis"},{"key":"1989_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909\u201317.","journal-title":"Clin Infect Dis"},{"key":"1989_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1080\/13693780400020113","volume":"43","author":"J Morgan","year":"2005","unstructured":"Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43:S49-58.","journal-title":"Med Mycol"},{"key":"1989_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/asheducation-2003.1.438","volume":"1","author":"SN O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Prog. 2003;1:438\u201372.","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"1989_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NR Stone","year":"2016","unstructured":"Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76:485\u2013500.","journal-title":"Drugs"},{"key":"1989_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"R Laniado-Laborin","year":"2009","unstructured":"Laniado-Laborin R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26:223\u20137.","journal-title":"Rev Iberoam Micol"},{"key":"1989_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","volume":"25","author":"JP Barrett","year":"2003","unstructured":"Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EGV, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C. Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25:1295\u2013320.","journal-title":"Clin Ther."},{"key":"1989_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1517\/14740338.2013.827168","volume":"12","author":"AS Loo","year":"2013","unstructured":"Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12:881\u201395.","journal-title":"Expert Opin Drug Saf"},{"key":"1989_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jiac.2018.04.014","volume":"24","author":"H Kato","year":"2018","unstructured":"Kato H, Hagihara M, Yamagishi Y, Shibata Y, Kato Y, Furui T, Watanabe H, Asai N, Koizumi Y, Mikamo H. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B. J Infect Chemother. 2018;24:725\u20138.","journal-title":"J Infect Chemother"},{"key":"1989_CR11","first-page":"206","volume":"25","author":"F \u00c1lvarez-Lerma","year":"2012","unstructured":"\u00c1lvarez-Lerma F, Soriano MC, Rodr\u00edguez M, Catal\u00e1n M, Llorente AM, Vidart N, Garitacelaya M, Marav\u00ed E, Fern\u00e1ndez E, Alvarado F, L\u00f3pez M, Alvarez-S\u00e1nchez B, Espinosa J, Quintana E. Study Group of Liposomal Amphotericin B in the ICU. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment. Rev Esp Quimioter. 2012;25:206\u201315.","journal-title":"Rev Esp Quimioter."},{"key":"1989_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","volume":"17","author":"O Penack","year":"2006","unstructured":"Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol. 2006;17:1306\u201312.","journal-title":"Ann Oncol"},{"key":"1989_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10147-012-0485-6","volume":"18","author":"S Noguchi","year":"2013","unstructured":"Noguchi S, Takahashi N, Ito M, Teshima K, Yamashita T, Michishita Y, Ohyagi H, Shida S, Nagao T, Fujishima M, Ikeda S, Ito I, Fujishima N, Kameoka Y, Saitoh H, Tagawa H, Hirokawa M, Sawada K. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. Int J Clin Oncol. 2013;18:983\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1989_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/AAC.38.4.713","volume":"38","author":"JW Lee","year":"1994","unstructured":"Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994;38:713\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1989_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002a;46:828\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"1989_CR16","first-page":"1743","volume":"61","author":"K Goto","year":"2012","unstructured":"Goto K, Makino T, Ohchi Y, Shiromi R, Tsubone T, Abe T, Yamamoto S, Yasuda N, Hidaka S, Noguchi T. Efficacy and safety evaluation of liposomal amphotericin B (L-AMB) for injection in patients with septic acute kidney injury during continuous renal replacement therapy (RRT). J New Rem Clin. 2012;61:1743\u201350.","journal-title":"J New Rem Clin"},{"key":"1989_CR17","first-page":"360","volume":"26","author":"F \u00c1lvarez-Lerma","year":"2013","unstructured":"\u00c1lvarez-Lerma F, Rodriguez M, Soriano MC, Catal\u00e1n M, Llorente AM, Vidart N, Garitacelaya M, Maravi E, Fern\u00e1ndez Rey E, Alvarado F, L\u00f3pez-S\u00e1nchez M, Alvarez-S\u00e1nchez B, Granado D, Quintana E. Study group of liposomal amphotericin B in the ICU. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy. Rev Esp Quimioter. 2013;26:360\u20138.","journal-title":"Rev Esp Quimioter."},{"key":"1989_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jac\/dkg139","volume":"51","author":"R Bellmann","year":"2003","unstructured":"Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Kaneider N, Dunzendorfer S, Wiedermann CJ. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother. 2003;51:671\u201381.","journal-title":"J Antimicrob Chemother"},{"key":"1989_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4009\/jsdt.48.163","volume":"48","author":"K Kajiwara","year":"2015","unstructured":"Kajiwara K, Tomita M, Okamura K, Nakagawa T, Sakanashi A, Miura R, Fujimoto K, Kajiwara N, Iwata Y, Nobuoka M, Matsunaga A, Yamamoto S, Oobayashi H, Yoshida K. Pharmacokinetics of liposomal amphotericin B during hemodialysis using polysulfone\/high-flux membrane. J Jpn Soc Dial Ther. 2015;48:163\u20137.","journal-title":"J Jpn Soc Dial Ther"},{"key":"1989_CR20","first-page":"342","volume":"60","author":"T Furukubo","year":"2012","unstructured":"Furukubo T, Tsuboniwa N, Katoh Y, Matsumoto K, Morita K, Matsunaga C, Maehara C, Izumi S, Shoji S, Yamakawa T. Long-term monitoring of serum amphotericin B in a hemodialysis patient receiving a liposomal preparation for Cryptococcus infection. Jpn J Chemother. 2012;60:342\u20136.","journal-title":"Jpn J Chemother"},{"key":"1989_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1248\/yakushi.130.87","volume":"130","author":"S Hidaka","year":"2010","unstructured":"Hidaka S, Goto K, Hagiwara S, Iwasaka H, Noguchi T. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi. 2010;130:87\u201394.","journal-title":"Yakugaku Zasshi"},{"key":"1989_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5649\/jjphcs.29.449","volume":"29","author":"K Matsumoto","year":"2003","unstructured":"Matsumoto K, Ueno K, Ishida S, Kusumoto S, Mitsutake K. Studies on therapeutic drug monitoring and evaluation of optimal dosage based on fluconazole pharmacokinetics. Jpn J Pharm Health Care Sci. 2003;29:449\u201356.","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"1989_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002b;46:834\u201340.","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1007\/s10157-020-02004-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-01989-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T20:23:00Z","timestamp":1627676580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-01989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01989-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-020-02004-5","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10157-020-02004-5","URL":"https:\/\/doi.org\/10.1007\/s10157-020-02004-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.I. received honorarium and research grant from Sumitomo Dainippon Pharma Co., Ltd. T.W. is a full-time employee of Sumitomo Dainippon Pharma Co., Ltd. A.T. and K.S. are full-time employees of Deloitte Tohmatsu Consulting LLC. Deloitte Tohmatsu Consulting LLC receives consulting fees from Sumitomo Dainippon Pharma Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or the national research committee at which the studies were conducted (IRB approval number 18033038-5) as well as the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As the data analyzed in the present study were anonymously processed by the database provider in accordance with the Act on the Protection of Personal Information of Japan and other related regulations, requirement for informed consent from the patients was waived according to the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare of Japan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}